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Abstract
BACKGROUND & AIMS—Aspirin reduces the incidence of and mortality from colorectal
cancer (CRC) by unknown mechanisms. Cancer cells have defects in signaling via the mechanistic
target of rapamycin (mTOR), which regulates proliferation. We investigated whether aspirin
affects adenosine monophosphate–activated protein kinase (AMPK) and mTOR signaling in CRC
cells.
METHODS—The effects of aspirin on mTOR signaling, the ribosomal protein S6, S6 kinase 1
(S6K1), and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) were examined
in CRC cells by immunoblotting. Phosphorylation of AMPK was measured; the effects of loss of
AMPKα on the aspirin-induced effects of mTOR were determined using small interfering RNA
(siRNA) in CRC cells and in AMPKα1/α2−/− mouse embryonic fibroblasts. LC3 and ULK1 were
used as markers of autophagy. We analyzed rectal mucosa samples from patients given 600 mg
aspirin, once daily for 1 week.
RESULTS—Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors
S6K1 and 4E-BP1. Aspirin changed nucleotide ratios and activated AMPK in CRC cells. mTOR
was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKα, indicating AMPK-
dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR. Aspirin
induced autophagy, a feature of mTOR inhibition. Aspirin and metformin (an activator of AMPK)
increased inhibition of mTOR and Akt, as well as autophagy in CRC cells. Rectal mucosal
samples from patients given aspirin had reduced phosphorylation of S6K1 and S6.
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CONCLUSIONS—Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting
regulators of intracellular energy homeostasis and metabolism. These could contribute to its
protective effects against development of CRC.
Keywords
Chemoprevention; Colon Cancer; Oncogene; Tumor Suppressor
Colorectal cancer (CRC) is common, with a worldwide incidence estimated at more than 1
million cases annually. Overall survival is poor, underscoring the rationale for new
preventative approaches. Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), reduces
cancer risk, particularly CRC.1,2 Primary prevention with aspirin is not currently
recommended because the risk:benefit ratio is finely balanced. NSAIDs inhibit cell growth
and induce apoptosis at various disease stages, from initiation to progression. Although
evidence that aspirin prevents cancer is compelling, the underlying molecular mechanism
remains enigmatic. Numerous molecular targets have been implicated but the antitumor
activity of aspirin cannot be attributed wholly to a single target. It is likely that aspirin
influences several molecular pathways and that the nonspecific nature of the effect may be
key to cancer prevention. Hence, the complex signaling effects of aspirin that lead to CRC
cell death require further elucidation.
Signaling via the serine/threonine kinase mechanistic target of rapamycin (mTOR) controls
cell survival and regulation of metabolism.3 mTOR is pivotal in assimilating growth factor,
nutrient, and signaling stimuli that regulate protein synthesis and growth.4 mTOR forms the
catalytic core of 2 distinct complexes, mTORC1 and mTORC2, both containing mLST8 and
DEPTOR proteins. In addition, mTORC1 consists of raptor and PRAS40, whereas
mTORC2 includes rictor, mSIN1, and protor. mTORC1 integrates growth factor and
nutrient signals to influence protein synthesis, growth, autophagy, and ribosomal biogenesis.
The role of mTORC2 is less well defined, involving cell survival and cytoskeleton
regulation. Furthermore, mTORC1 regulates mTORC2 through rictor phosphorylation by S6
kinase 1 (S6K1), adding further complexity to mTOR regulation.5,6
Substantial evidence implicates dysregulated phosphoinositide-3-kinase (PI3K)/mTOR
signaling in cancer development, including CRC. Mutations in PI3K signaling genes occur
in 40% of CRCs.7 Raptor, rictor, and mTOR itself are overexpressed in CRCs.8 The role of
mTOR in cancer biology is strengthened by evidence that negative regulators of mTOR are
tumor suppressors. PTEN, which down-regulates mTOR, is inactivated in 30%–40% of
CRCs.9 Unconstrained mTOR signaling, via effectors S6K1 and 4E-BP1, promotes tumor
growth by enhancing translation and protein synthesis. Activation of the adenosine
monophosphate–activated protein kinase (AMPK), a critical cellular energy sensor, leads to
mTOR suppression. AMPK is activated by liver kinase B1 (LKB1), a tumor-suppressor
gene inactivated by germline mutations in Peutz–Jeghers syndrome, a CRC susceptibility
disorder.10 LKB1 tumor-suppressor activity is caused partly by AMPK-mediated inhibition
of inappropriate mTOR activation.11 Indeed, AMPK activation by pharmacologic activators
5-Aminoimidazole-4-carboxyamide ribonucleoside (AICAR) and metformin inhibits growth
in several cancers.12 Furthermore, treatment of tumor-prone PTEN+/− / LKB1 hypomorphic
mice with AMPK activators including A-769662, metformin, and phenformin delays tumor
onset.13
Clinical trials of mTOR inhibitors have been disappointing, especially for solid tumors.
Studies using rapamycin, mainly targeting mTORC1, have highlighted feedback signaling,
which counters mTOR inhibition by increasing Akt via S6K/IRS-1.14 Adenosine
triphosphate (ATP)-competitive inhibitors targeting both mTORC1 and mTORC2 catalytic
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sites have been developed, but some increase Akt despite S6K1 inhibition, suggesting that
increased Akt signaling as a result of mTORC1 inhibition overwhelms mTORC2
inhibition.15 Hence, the latest generation inhibitors specifically target mTORC2 to avoid
feedback caused by mTORC1 inhibition.16 However, the very specificity of such agents
may be problematic, whereas drugs targeting several components within the same pathway
may circumvent signaling redundancy.17 Furthermore, the long-term safety profile of such
drugs is unknown, and so their use for chemoprevention is not appropriate.18
Much available evidence supports AMPK/mTOR signaling as a chemoprevention target. We
hypothesize that pathway modulation is a mechanism by which aspirin exerts antitumor
effects. Here, we investigate the effects of aspirin on AMPK/mTOR signaling and provide
novel insight into the mechanism of action of aspirin as a chemopreventive agent in CRC.
Materials and Methods
Antibodies and Reagents
Details are provided in Supplementary Table 1.
Cell Line Culture and Treatment
CRC cell lines (RKO, SW480, and HCT116) are available from the American Type Culture
Collection (Middlesex, UK). Professor Bert Vogelstein kindly provided HCT116 Akt1/Akt2
knockout cells.19 Dr Benoit Viollet kindly provided AMPK α1/α2 knockout mouse
embryonic fibroblasts (MEFs).20 Cells grown as monolayers in respective media
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin were treated at
60%–70% confluence.
Immunoblotting
Cells were lysed in ice-cold, whole-cell lysis buffer (buffer details are available in the
Supplementary Materials and Methods section). For cytoplasmic and nuclear extraction,
cells were lysed in cytoplasmic lysis buffer, nuclei pelleted, and lysed in hypotonic buffer
(30 minutes). Protein was measured by the Bradford method (Bio-Rad, Hemel Hempstead,
UK). Lysates separated on sodium dodecyl sulfate–polyacrylamide gel electrophoresis were
transferred to a polyvinylidene difluoride membrane and blocked in 4% nonfat milk with
0.3% Tween20 (Sigma-Aldrich, St. Louis, MO). Antigen-antibody complexes were
visualized with chemiluminescence (Amersham, GE Healthcare, Little Chalfont, UK).
AMPK Activity Assay
AMPK was immunoprecipitated from 50 μg lysate with antibodies against AMPK α1 and
assayed for phosphotransferase activity toward AMARA peptide using [γ-32P]ATP, as
previously described.21
Nucleotide Measurements
Cells were rinsed with ice-cold phosphate-buffered saline (PBS) before addition of 5%
perchloric acid to extract nucleotides and centrifuged to remove debris. An equal volume of
a 1:1 mix of 1,1,2 trichlorotrifluoroethane and trioctylamine was added to supernatant.
Samples were vortexed, centrifuged, and the upper aqueous layer was collected. This
organic extraction was repeated twice before separation by capillary electrophoresis with
oncolumn isotachophoretic concentration.22
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Small Interfering RNA
Two small interfering RNA (siRNA) corresponding to bases 238–256 and 267–285 of
human AMPKα1 open reading frame (NCBI Reference Sequence: NM_006251.5): 5′-CCU
CAA GCU UUU CAG GCA Utt-3′ and 5′-UUA AAC UGU ACC AGG UCA Utt-3′ were
co-transfected to maximize knockdown (Ambion, Austin, TX). Nonspecific siRNA was
used as negative control. At 60% confluence cells were transfected in antibiotic-free
McCoy’s 5A medium (10% fetal calf serum). Transfection (50 or 100 pmol/mL) was
performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and Opti-MEM
(Invitrogen). Fresh medium was added 6 hours after transfection. Transfection medium was
removed after 48 hours and experiments were performed 16 hours later.
Immunofluorescence
Cells grown to 60%–70% confluence on glass coverslips in 6-well plates were treated with
aspirin, metformin, or carrier for 16 hours. After treatment, cells were washed with PBS,
fixed with acetone:methanol (−20°C, 10 minutes), and blocked in 10% nonimmune goat
serum (Sigma) for 1 hour. LC-3 antibody (Nanotools, Teningen, Germany) was applied (1
h) followed by incubation (1 hr) with Alexa Fluor 594 F(ab′)2 fragment of goat anti-mouse
IgG (Invitrogen). Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI).
Animal Studies
All animal studies were approved by the University of Dundee Ethics Committee and
performed under a UK Home Office project license. Groups of 4 female C57BL/6J mice
were given aspirin or phenformin in drinking water (aspirin, 400 mg/kg; phenformin, 300
mg/kg/day). Drugs were dissolved from powder every day into drinking water, taking into
account mouse body weight and the volume of water consumed each day. No other water
was available, and the volume of water consumed by each mouse per day was noted and
used to calculate the dose of drugs required. The mice were maintained under standard
husbandry conditions and monitored for body weight and water and food intake
(Supplementary Figure 1). The aspirin dose was escalated to 100% by day 5 and phenformin
by day 15. At day 21 mice were euthanized and organs were harvested. All animal
experiments were performed in accordance with UK Coordinating Committee on Cancer
Research (UKCCR) guidelines.23
Patient Studies
Three patients were treated with 600 mg aspirin once daily for 7 days. The exclusion criteria
were current/recent ingestion of NSAIDs or any contraindication to NSAIDs. The study had
ethical and management approval (local research ethics committee number 99/5/8 and
clinical trial authorisation number 17844/0001/001). After informed consent, biopsy samples
were taken from normal rectal mucosa before, and at 4 hours, 24 hours, and after 7 days of
aspirin treatment.
Results
Aspirin Inhibits mTOR Signaling and Induces AMPK in CRC Cells
We investigated aspirin’s effects on the mTORC1 target proteins S6K1, its substrate S6
ribosomal protein (S6), and 4E-BP1 in 3 CRC cell lines: RKO, SW480, and HCT116. These
cell lines represent CRC as a whole and differ in their mutation profile with respect to
mTOR pathway genes (Supplementary Table 2).
We used 5 mmol/L aspirin for stimulation having previously observed apoptosis with this
concentration in CRC cells.24 There was a striking decrease in S6K1 phosphorylation at 10
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minutes and an overall decrease at 16 hours in all CRC cell lines after aspirin (Figure 1A).
Aspirin decreased S6 phosphorylation at sites specific to S6K1 at 8 and 16 hours in all cell
lines (Figure 1A). Decreased S6K1 phosphorylation at 10 minutes did not translate into an
immediate decrease in S6 phosphorylation, suggesting the presence of intermediate steps.
We examined aspirin effects on the other well-characterized mTORC1 target 4E-BP1. When
phosphorylated by mTORC1, 4E-BP1 dissociates from eIF4E which initiates cap-dependent
translation. Hypophosphorylated 4E-BP1 binds eIF4E, thereby inhibiting translation.
Aspirin decreased phosphorylation of 4E-BP1 in CRC cells (Figure 1B). These results
suggest that aspirin exerts an inhibitory effect on mTORC1 signaling. We confirmed
increased expression of phosphorylated proteins of S6K1, S6, and total 4E-BP1 in CRC
tissue, compared with matched normal tissue (Supplementary Figure 2).
We next examined whether aspirin’s inhibitory effects on mTOR signaling were explained
by AMPK activation. Aspirin increased phosphorylation of AMPK at Thr172, which reflects
AMPK activity, at 10 minutes in all CRC cell lines (Figure 1C). This generally was
sustained for 1–2 hours, with a further increase at 16 hours. Phosphorylation of acetyl-CoA
carboxylase (ACC), a well-established AMPK substrate, may be a more accurate
representation of AMPK enzyme activity. Enhanced AMPK phosphorylation was paralleled
by increased phosphorylation of ACC that was sustained up to 16 hours (Figure 1C). We
further confirmed that aspirin stimulates AMPK activity by performing quantitative kinase
assays, which reflected the phosphorylation state of AMPK and ACC (Figure 1D). We
confirmed that salicylate (aspirin metabolite) induces AMPK and ACC phosphorylation at 1
and 5 hours. There is evidence of decreased S6 phosphorylation at 8 and 16 hours and
decreased 4E-BP1 at 16 hours (Supplementary Figure 3).
Nucleotide fluctuation increases the AMP:ATP ratio and activates AMPK, therefore we
assessed whether aspirin influences nucleotides in CRC. Consistent with previous data,22
basal AMP levels were below capillary electrophoresis detection limits but AMP was
evident in aspirin-treated CRC cells. In line with previous work,22 we used the adenosine
diphosphate (ADP):ATP ratio as a surrogate for AMP:ATP variation. If the ADP:ATP ratio
increases by 5-fold, the AMP:ATP ratio increases by 25-fold, providing the adenylate kinase
reaction is in equilibrium.25 There is a 2.8-fold increase in the ADP:ATP ratio and a 10-fold
increase in the derived AMP:ATP ratio after 4 hours of aspirin exposure (Supplementary
Table 3). The magnitude of increase in the ADP:ATP ratio with aspirin is similar to that
with mitochondrial and glycolytic 2-deoxyglucose (2-DG) inhibitors.22 Taken together with
the effects on AMPK and ACC phosphorylation and AMP kinase activity, these results
definitively show that aspirin activates AMPK in CRC cells.
Dependency of Aspirin-Mediated mTOR Inhibition on AMPK Activation
To investigate whether aspirin-induced mTOR inhibition is caused by AMPK activation, we
aimed to abrogate the aspirin-induced AMPK response in CRC cells using siRNA to silence
the AMPKα catalytic subunits. Given AMPKα1 was the predominant isoform in RKO cells
(Figure 2A), transfection was performed with 2 siRNAs to AMPKα1 that knockdown both
AMPK and ACC.26 Although siRNA inhibition of AMPKα1 reduced both AMPK and ACC
phosphorylation in response to aspirin, this did not attenuate aspirin-induced inhibition of
S6K1 and S6 phosphorylation (Figure 2B). However, total AMPK was not completely
silenced, raising the possibility of residual kinase activity. The response to AMP is finely
tuned and small increases in AMP lead to large changes in AMPK signaling. Nonetheless,
these findings suggest that attenuating aspirin-induced AMPK activation does not exert
equivalent abrogation of aspirin’s inhibitory effects on mTOR signaling.
To further explore the dependency of aspirin-induced mTOR inhibition on AMPK
activation, we used AMPK MEFs with both catalytic subunits genetically deleted. Notably,
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the cellular energy status is not affected in AMPK knockout compared with wild-type
MEFs.27 Similar to CRC cells, aspirin increased AMPK and ACC phosphorylation in
parental MEFs (AMPKα1/α2+/+), although there were no detectable signals in
AMPKα1/α2−/− knockout MEFs (Figure 2C and Supplementary Figure 4). However, aspirin
decreased both S6K1 and S6 phosphorylation in parental and AMPKα1/α2−/− MEFs (Figure
2C and Supplementary Figure 4). Together with siRNA results, these findings indicate that
aspirin may induce mTOR inhibition through both AMPK-dependent and AMPK-
independent mechanisms.
Influence of Akt on AMPK Activation and mTOR Inhibition and Effects on mTORC2
Given that Akt may affect both AMPK and mTOR, we investigated whether Akt signaling
influences aspirin-induced AMPK activation and mTOR inhibition using cells with AKT1
and 2 deleted (HCT116 Akt1/2−/−).19 Akt expression was confirmed (Supplementary Figure
5). Aspirin increased AMPK and ACC phosphorylation in both parental and HCT116
Akt1/2−/− cells (Figure 3A). Indeed, the effect on AMPK/ACC is greater in the absence of
Akt. We next examined whether Akt influenced aspirin-mediated effects on mTOR
signaling. Although there was less phosphorylated S6K1 in untreated HCT116 Akt1/2−/−
cells compared with parental cells, aspirin decreased S6K1 and S6 phosphorylation in both
cell lines at 10 minutes and 16 hours (Figure 3A). These results indicate that aspirin-induced
AMPK activation and mTOR inhibition are not secondary to Akt signaling. Phosphorylation
of the SGK1 substrate, NDRG1, is a robust marker of mTORC2. Aspirin decreased NDRG1
phosphorylation in RKO cells but not in HCT116 cells (Figure 3B). Further experimentation
is required to establish whether the effects of aspirin on mTORC2 are cell-type specific.
Aspirin Combined With Metformin Enhances AMPK Activation and mTOR Inhibition
Results thus far establish that aspirin acts on AMPK and mTOR, both key regulators of
cellular energy and metabolism. We next investigated whether aspirin combined with a
known AMPK activator would have an additive effect on mTOR inhibition because aspirin
effects may not saturate the potential AMPK response. Metformin, a known AMPK
activator, inhibits Akt28 and this was confirmed in RKO cells (Figure 4A). Aspirin and
metformin combination treatment resulted in greater AMPK activation than either agent
alone after 10 minutes, and activation was attenuated only marginally at 16 hours (Figure 4B
and C). AMPK activation was paralleled by a marked decrease in Akt phosphorylation at 10
minutes, remaining detectable at 16 hours. Neither agent alone decreased S6
phosphorylation, examined as an end point of mTOR signaling, at 10 minutes, but there was
a substantial decrease with combination treatment, which was sustained at 16 hours (Figure
4B and C). These results show that the combination of aspirin and metformin has a striking
additive effect on AMPK activation and mTOR inhibition.
Aspirin Induces Autophagy in CRC Cells
Having established that aspirin modulates mTOR signaling in CRC cells through composite
effects on pathway components, we explored resultant cell biological outcomes. Aspirin
inhibits cell proliferation and induces apoptosis.24,29 As expected, aspirin increased cleaved
caspase-3 and reduced proliferating cell nuclear antigen (PCNA) levels in CRC cells (Figure
5A and B), consistent with apoptosis and inhibition of proliferation. We also examined the
RNA binding protein human antigen R (HuR) given its relevance to CRC cell proliferation.
HuR cellular localization determines its ability to influence messenger RNA (mRNA)
stability by binding adenylateuridylate–rich elements of labile mRNAs. HuR is located in
nuclei of unstimulated cells and mRNA-stabilizing properties rely on cytoplasmic
translocation. AMPK decreases cytoplasmic HuR and binding to target transcripts30 and
HuR regulates stability of cyclins.31 Aspirin decreased cytoplasmic HuR and cyclin A in
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CRC cells (Figure 5B). Taken together these results confirm that aspirin inhibits
proliferation and induces apoptosis.
mTOR negatively regulates autophagy and therefore we assessed aspirin’s effects on
autophagy. LC3 is a commonly used autophagy marker and its processed form, LC3-I,
resides in cytoplasm. After autophagy induction, LC3-II, the conjugated form of LC3,
associates with autophagosomes. However, an increase in autophagosomes alone, suggested
by increased LC3-II, does not necessarily indicate increased autophagy.32 Increases in LC3-
II after pretreatment with a lysosomal inhibitor, such as bafilomycin A, signify a true
increase in autophagic flux. Aspirin increased LC3-II in HCT116 cells, which is increased
further with bafilomycin A pretreatment, suggesting induction of autophagy (Figure 5C).
Immunofluorescence confirmed increased LC3 detection after aspirin alone and in
combination with metformin (Figure 5D). AMPK phosphorylates ULK1, the mammalian
homologue of Atg1, which initiates autophagy.33,34 We found that aspirin induces ULK1
phosphorylation at Ser555 in RKO cells (Figure 5E). Aspirin-induced ULK1
phosphorylation was abrogated in AMPKα1/α2−/− MEFs, indicating AMPK dependency
(Figure 5E). Aspirin decreases phosphorylation of ULK at serine 757, suggesting inhibition
of mTOR also may contribute to autophagy induction in CRC cells (Figure 5E). However,
aspirin induced autophagy, evidenced by increased LC3, in AMPKα1/α2−/− MEFs,
indicating an AMPK-independent contribution (Figure 5F). Notably, aspirin also induces
autophagy in HCT116 Akt1/2−/− cells (Figure 5F). These results show that aspirin induces
autophagy in CRC cells, likely through both direct AMPK-mediated ULK1 phosphorylation
and by inhibiting mTOR signaling.
Aspirin Affects AMPK and mTOR Signaling In Vivo
We performed a short-term experiment over 21 days in control mice to investigate whether
aspirin induces AMPK activation in vivo. We found evidence of both AMPK and ACC
phosphorylation in livers of aspirin-treated mice (Figure 6Ai). Aspirin increased AMPK
phosphorylation in the colon of treated mice. Increased ACC phosphorylation was
detectable in 3 of 4 mouse colons.
We also undertook a short-term biological-response study in normal rectal mucosa of
patients treated with aspirin. S6 was the most robust marker of mTOR inhibition with some
variation in basal levels in untreated patients (Figure 6Bi). Three patients were given 600 mg
aspirin orally once daily for 7 days. Normal rectal mucosa was biopsied before treatment
and at 4 hours, 24 hours, and 7 days. We found that aspirin decreases S6 phosphorylation in
normal rectal mucosa (Figure 6Bii) and there is some decrease in phosphorylation of S6K1
(Figure 6Biii). These results suggest that aspirin when ingested orally can modulate effectors
of mTOR in vivo.
Discussion
Here, we show that aspirin inhibits mTOR signaling in CRC cells, as evidenced by
inhibition of phosphorylation of S6K1, 4E-BP1, and S6. We show that aspirin activates
AMPK in CRC cells. Furthermore, we show that aspirin induces autophagy in CRC cells, a
response characteristic of mTOR inhibition. Our results support the concept that aspirin
affects multiple components of the AMPK/mTOR signaling pathway.
mTORC1 plays a key role in protein synthesis regulation via its effectors S6K1 and 4E-BP1.
Constitutively activated mTOR signaling has been shown previously in CRC. Indeed,
several ribosomal proteins are up-regulated in CRC, including the S6K1 target S6.35
Targeted mTOR inhibition decreases adenoma formation in a mouse familial adenomatous
polyposis model36 and also inhibits CRC cell growth. Our results show (to our knowledge,
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for the first time), in CRC cells, that aspirin inhibits the downstream effectors of mTORC1:
S6K1, 4E-BP1, and S6. These results are consistent with microarray data showing that
aspirin induces the greatest changes in ribosome biogenesis genes.37 S6K1 deletion in mice
results in defective ribosomal biogenesis and disruption of a single ribosomal protein shuts
down ribosomal synthesis.38 Given the striking decrease in S6K1, it will be important to
evaluate whether aspirin affects ribosomal synthesis both in normal colon and in CRCs from
both chemopreventive and adjuvant perspectives.
It was important to determine whether aspirin-mediated mTOR inhibition was related to the
upstream kinase AMPK. AMPK can inhibit mTORC1 through phosphorylation of TSC2,
which enhances GAP activity toward Rheb, or via a TSC2-independent mechanism by direct
phosphorylation of raptor, which induces 14-3-3 binding to raptor.39,40 Treatment with
known AMPK activators leads to mTOR inhibition and decreased growth in CRC cells and
mouse adenoma models.13,41 Our results show (to our knowledge, for the first time) that
aspirin activates AMPK in CRC cells, confirmed by kinase assays and demonstration of
ACC phosphorylation, supporting the perception that AMPK has a tumor-suppressor role.12
Furthermore, phosphorylated AMPK expression has been shown to be associated with
improved survival in a subset of CRCs.42
Our data from siRNA experiments in CRC cells and AMPK MEFs indicate that aspirin-
induced AMPK activation is not the sole determinant of observed mTOR inhibition.
Although the effects of aspirin on AMPK/mTOR signaling in MEFs may not be
representative of all somatic mutations arising in human CRCs, these experiments provide a
model for so called normal cells representing normal colonic epithelium, which is relevant
to chemoprevention. Our data are consistent with mTOR effects being AMPK-independent
but we cannot exclude an AMPK-dependent contribution.
Recently, it was shown that AMPK is not required for mTORC1 inhibition after glycolytic
blockage by energy-depleting agents (2DG) or known AMPK activators.27 An alternative
mechanism of mTORC1 inhibition via RAG guanosine triphosphatase inhibition is
suggested. Indeed, aspirin may mediate mTORC1 inhibition via similar effects on RAG
function. Combination treatment with 2-DG and metformin led to apoptosis in prostate
cancer cells via ATP depletion and AMPK activation.43 Similarly, aspirin may induce
changes in ATP with ensuing alterations in AMP:ATP ratios, and/or inhibition of the
mitochondrial chain complex. Both aspirin and salicylate have been shown to uncouple
mitochondrial oxidative phosphorylation. The results presented here show that aspirin
increases the ADP:ATP ratio, an established surrogate for the AMP:ATP ratio. It is clear
that the upstream mechanisms underlying aspirin-induced AMPK activation merit further
investigation.
We have shown that aspirin activates AMPK and inhibits mTOR signaling in CRC cells.
The key question is where the balance lies in terms of mTOR inhibition and cellular
response to aspirin. Here, we show in CRC cells that aspirin induces a cellular phenotype
characteristic of mTOR inhibition, namely autophagy. During autophagy lysosomes digest
their own cytoplasmic organelles to generate energy.44 Substantial evidence indicates that
AMPK/mTOR signaling regulates autophagy.45 Some previous reports have suggested that
some NSAIDs induce autophagy.46,47 We show that aspirin does induce autophagy, likely
through AMPK phosphorylation of ULK1 and also an AMPK-independent mechanism of
mTOR inhibition. That aspirin induces autophagy in AMPKα1/α2−/− MEFs strengthens the
probability of AMPK-independent input. Concerns with mTOR inhibition are the potential
for feedback-initiated Akt activation. Our results suggest that the predominant aspirin-
induced cellular response is one of mTOR inhibition (autophagy) rather than Akt activation
(cellular proliferation and inhibition of apoptosis). Signaling between mTOR and Akt
DIN et al. Page 8
Gastroenterology. Author manuscript; available in PMC 2013 June 14.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
appears to exist in balance and inter-regulatory pathways likely have evolved to restrain
hyperactivation of both.48 Indeed, we show the added value, in terms of both mTOR and
Akt inhibition, of combining aspirin with metformin.
Combination treatment is a particularly attractive strategy to combat the metabolic
syndrome, characterized by hyperinsulinemia, insulin resistance, obesity, type 2 diabetes,
and hypertension. There is a strong association between the metabolic syndrome and
colorectal neoplasia.49 Furthermore, metabolic syndrome may adversely affect the
propensity of CRC to metastasize and relapse, impacting survival.50 Considerable evidence
indicates that physical inactivity is associated with increased cancer risk.51 Because exercise
activates AMPK, we speculate that AMPK and mTOR may be linked mechanistically to the
cancer-protection effects of exercise. Indeed, the absence of S6K1 protects mice from both
age- and diet-related obesity and enhances insulin sensitivity.52 As master regulators of
cellular energy and insulin signaling, both AMPK and mTOR highlight the association
between the metabolic syndrome and CRC, and present ideal targets for intervention.
A small-molecule approach directed at a single target to effect cancer cure remains elusive,
and may even activate signaling detrimentally through normally redundant pathways. It is
recognized that mutations in genes encoding PI3K/mTOR and RAS pathways in CRC cell
lines influence response and combined inhibition is required to inactivate mTOR.53 Thus,
development of several agents, each targeting different signaling switches, may have greater
efficacy with reduced side effects. We have shown that aspirin targets the AMPK/mTOR
signaling pathway at several levels in CRC cells, thus gaining new understanding of the
molecular mechanisms underlying the antitumor activity of aspirin (Figure 7). Furthermore,
we have shown that metformin may be used in a concerted manner to inhibit the mTOR
pathway in CRC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used in this paper
ACC acetyl-CoA carboxylase
ADP adenosine diphosphate
AMPK adenosine monophosphate–activated protein kinase
ATP adenosine triphosphate
CRC colorectal cancer
eIF4E eukaryotic translation initiation factor 4E
4E-BP1 4E, binding protein 1
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HuR human antigen R
LC3 light chain 3
MEF mouse embryonic fibroblast
mRNA messenger RNA
mTOR mechanistic target of rapamycin
NDRG1 N-myc downstream regulated 1
NSAID nonsteroidal anti-inflammatory drug
PBS phosphate-buffered saline
PI3K phosphoinositide-3-kinase
siRNA small interfering RNA
S6 S6 ribosomal protein
S6K1 S6 kinase 1
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Figure 1.
Aspirin inhibits mTOR and activates AMPK in CRC cells. Aspirin-treated CRC whole-cell
lysates were immunoblotted. Aspirin inhibits phosphorylation of (A) S6K1, S6 ribosomal
protein (S6), and (B) 4E-BP1 in CRC cells. (C) Aspirin induces phosphorylation of AMPK
and its substrate ACC in CRC cells. Imagequant software (GE Healthcare, Little Chalfont,
UK) was used for densitometry, which is presented as the ratio of phosphorylated to total
protein corrected for actin. Phenformin-treated CRC cells were used as controls. AMPK was
immunoprecipitated from aspirin-treated whole-cell lysates and assayed with the AMARA
peptide. (D) Aspirin increases AMPK activity in HCT116 cells (mean of 3 independent
experiments).
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Figure 2.
AMPK depletion, siRNA-mediated or genetic, does not attenuate aspirin-induced mTOR
inhibition. RKO cells, transfected with siRNA against (Ai) AMPK α1, (Aii) α2, or control
(con) for 48 hours, were probed as noted. (B) Lysates from aspirin-treated RKO cells
transfected with AMPKα1 siRNA were immunoblotted. (C) Lysates from aspirin-treated
AMPKα1/α2−/− knockout MEFs and parental cells (wild type [WT]) were immunoblotted.
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Figure 3.
Influence of Akt on AMPK activation and mTOR inhibition and effects on mTORC2.
Whole-cell lysates from (Ai) 10-minute or (Aii) 16-hour aspirintreated HCT116 Akt1/2
knockout and parental (wild type [WT]) cells immunoblotted (duplicate experiments
presented). (B) Aspirin-treated CRC cells immunoblotted for p-NDRG1.
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Figure 4.
Dual targeting of AMPK, Akt, and mTOR signaling with aspirin and metformin. (A)
Metformin decreases Akt phosphorylation and increases AMPK phosphorylation in RKO
cells. RKO cells were treated with metformin alone, metformin and aspirin, aspirin after
pretreatment with metformin (10 minutes), or aspirin alone at concentrations indicated for
(B) 10 minutes or (C) 16 hours. Representative results are presented in duplicate.
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Figure 5.
Aspirin induces apoptosis, inhibition of cell proliferation, and autophagy in CRC cells.
Aspirin- or TNF-related apoptosis-inducing ligand (TRAIL) (10 ng/mL) treated CRC cells
were lysed and whole-cell, cytoplasmic (CE), or nuclear (NE) extracts were immunoblotted.
(A) Aspirin increases cleaved caspase-3 in CRC cells. (B) Aspirin decreases proliferating
cell nuclear antigen (PCNA) in both cytoplasmic and nuclear CRC cell extracts. Aspirin
decreases cytoplasmic HuR and cyclin A in CRC cells. (C) Aspirin increases LC3-II in
HCT116 cells pretreated with bafilomycin A. (D) Increased endogenous LC3 staining in
aspirin-, metformin-, or combination-treated RKO cells confirms autophagy at 16 hours.
Aspirin induces ULK1 Ser555 phosphorylation in RKO cells but not in AMPKα1/α2−/−
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knockout MEFs. DAPI, 4′,6-diamidino-2-phenylindole. (E) Aspirin decreases ULK1 Ser757
phosphorylation in HCT and RKO cells. (F) Aspirin increases LC3-II in both
AMPKα1/α2−/− MEFs and HCT116 Akt1/2 knockout and respective parental cells.
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Figure 6.
Aspirin activates AMPK and inhibits mTOR in vivo. Aspirin activates AMPK and ACC
phosphorylation in (Ai) liver and (Aii) colon from mice treated with aspirin or phenformin
for 21 days (aspirin, 400 mg/kg; phenformin [PHEN], 300 mg/kg body weight). (Bi) Basal
untreated total S6 levels in normal rectal mucosa of 3 patients. (Bii & Biii) Aspirin-treated
patients (600 mg once-daily [OD], 7 days) show decreased S6 and S6K1 phosphorylation in
normal rectal mucosa. Respective graphs show mean densitometry values of
phosphorylated:total protein, corrected for actin ± standard error. P, 5mM phenformin; S,
serum shock.
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Figure 7.
Aspirin targets multiple components of the AMPK/mTOR signaling pathway in colorectal
cancer. Aspirin increases phosphorylation of AMPK and ULK1. Aspirin inhibits mTOR
signaling as evidenced by decreased phosphorylation of S6K1, S6, and 4E-BP1. Hence,
aspirin is targeting multiple cellular pathways involved in mRNA stability, cell cycle,
autophagy, protein translation, and ribosome biogenesis.
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